A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

NCT00546715 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Daclatasvir
DRUG: Placebo

Sponsor

Bristol-Myers Squibb